Frank Zhang has been the Head of Global Pricing and Market Access for Immunology and Inflammation franchise of Celgene Corporation since 2010. His responsibilities cover five key global functions for Celgene I&I, including Pricing and Market Access, Global Health Economics, Global Outcomes Research, Patient Reported Outcomes (PRO), and Strategic Data Analytics. With his leadership, Otezla has been approved for pricing and reimbursement in over 20 countries within 2-year of global launch. Prior to Celgene, Frank led global Pricing and Health Economics for J&J’s Virology Franchise with successful launch of Incivo/Incivek and Intelence. He was US Outcomes Research lead for Concerta and Effexor in earlier part of his career. Frank is a physician by training with a Master of Public Health degree from Yale University.